GERON CORP Interest Expense Nonoperating
GERON CORP (GERN) reported Interest Expense Nonoperating of $7.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-05
- GERON CORP interest expense nonoperating for the quarter ending 2026-06-30 was $7.15M, a 16.09% decline year-over-year.
- GERON CORP interest expense nonoperating for the quarter ending 2026-03-31 was $7.15M, a 12.84% decline year-over-year.
- GERON CORP interest expense nonoperating for the quarter ending 2025-12-31 was $7.30M, a 16.18% decline year-over-year.
- GERON CORP interest expense nonoperating for the quarter ending 2025-09-30 was $8.64M, a 183.78% increase year-over-year.
- GERON CORP interest expense nonoperating for fiscal 2025 was $32.66M, a 76.49% increase from fiscal 2024.
- GERON CORP interest expense nonoperating for fiscal 2024 was $18.50M, a 122.62% increase from fiscal 2023.
- GERON CORP interest expense nonoperating for fiscal 2023 was $8.31M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.15M 10-Q · filed 2026-08-05 | $14.29M 10-Q · filed 2026-08-05 | $21.59M derived: sum of 3 quarters · filed 2026-08-05 | $30.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $7.15M 10-Q · filed 2026-05-06 | $14.44M derived: sum of 2 quarters · filed 2026-05-06 | $23.09M derived: sum of 3 quarters · filed 2026-05-06 | $31.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $15.94M derived: sum of 2 quarters · filed 2026-03-02 | $24.46M derived: sum of 3 quarters · filed 2026-08-05 | $32.66M 10-K · filed 2026-03-02 |
| 2025-09-30 | $8.64M 10-Q · filed 2025-11-07 | $17.16M derived: sum of 2 quarters · filed 2026-08-05 | $25.36M 10-Q · filed 2025-11-07 | $34.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $8.52M 10-Q · filed 2026-08-05 | $16.72M 10-Q · filed 2026-08-05 | $25.42M derived: sum of 3 quarters · filed 2026-08-05 | $28.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $8.20M 10-Q · filed 2026-05-06 | $16.91M derived: sum of 2 quarters · filed 2026-05-06 | $19.95M derived: sum of 3 quarters · filed 2026-05-06 | $23.27M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $8.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $11.75M derived: sum of 2 quarters · filed 2026-03-02 | $15.07M derived: sum of 3 quarters · filed 2026-03-02 | $18.50M 10-K · filed 2026-03-02 |
| 2024-09-30 | $3.05M 10-Q · filed 2025-11-07 | $6.37M derived: sum of 2 quarters · filed 2025-11-07 | $9.80M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $3.32M 10-Q · filed 2025-08-06 | $6.75M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $3.43M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $8.31M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |